MRNA vs ALNY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ALNY Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alnylam Pharmaceuticals, Inc. (ALNY) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus ALNY at 14.5x Forward P/E and 19.5% operating margin (+16.7% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against ALNY sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MRNA Revenue | ALNY Revenue | MRNA Op. Margin | ALNY Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $140M | $70M | -306.0% | -1087.6% | MRNA |
| FY2019 | $60M | $220M | -906.8% | -427.5% | ALNY |
| FY2020 | $800M | $490M | -95.0% | -168.1% | MRNA |
| FY2021 | $18.5B | $840M | 72.0% | -83.9% | MRNA |
| FY2022 | $19.3B | $1.04B | 48.9% | -75.7% | MRNA |
| FY2023 | $6.85B | $1.83B | -61.9% | -15.4% | ALNY |
| FY2024 | $3.24B | $2.25B | -121.9% | -7.9% | ALNY |
| FY2025 | $1.94B | $3.71B | -158.1% | 13.5% | ALNY |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MRNA | ALNY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $80.7B | $19.8B | Larger Scale | MRNA |
| Trailing P/E Ratio Valuation | 23.0x | 7.5x | Lower Multiple | ALNY |
| Forward P/E Ratio Valuation | 23.0x | 14.5x | Lower Multiple | ALNY |
| Revenue Growth (YoY) Growth | +29.2% | +16.7% | Higher Growth | MRNA |
| Operating Margin (TTM) Profitability | -80.8% | 19.5% | Higher Margin | ALNY |
| Net Profit Margin Profitability | -110.5% | 52.8% | Higher Margin | ALNY |
| Return on Equity (ROE) Capital Efficiency | -34.5% | 138.1% | Higher ROE | ALNY |
| 52-Week Range Position Momentum | 67% ($22โ$281) | 0% ($143โ$477) | Stronger Trend | MRNA |
| Beta / 30D Volatility Risk Regime | 2.23ฮฒ ยท 78% Vol | 0.54ฮฒ ยท 94% Vol | Lower Realized Risk | MRNA |
| Unified Institutional Score Composite Signal | 40.3 / 100 (SELL) | 48.8 / 100 (HOLD) | Higher Composite | ALNY |